I-Mab Biopharma Sustainability Profile
I-Mab Biopharma, a leading biopharmaceutical company headquartered in China, focuses on the discovery and development of innovative therapies for cancer and autoimmune diseases. Founded in 2015, I-Mab has rapidly established itself in the global biopharma landscape, with significant operational presence in both China and the United States. The company is renowned for its robust pipeline of monoclonal antibodies and proprietary drug candidates, which are designed to address unmet medical needs. Notable achievements include strategic partnerships and collaborations that enhance its research capabilities and market reach. With a commitment to advancing healthcare through cutting-edge science, I-Mab Biopharma continues to position itself as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes worldwide.
DitchCarbon Score
How does I-Mab Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
I-Mab Biopharma's score of 20 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
I-Mab Biopharma's reported carbon emissions
I-Mab Biopharma, headquartered in China (CN), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. In the absence of specific emissions data or commitments, it is important to note that many organisations in the biopharmaceutical sector are increasingly focusing on sustainability and climate action. This includes setting science-based targets and engaging in initiatives aimed at reducing their carbon footprint. However, without specific commitments or data from I-Mab Biopharma, it is unclear how they align with these industry trends. As the company continues to operate, it may consider adopting climate strategies that reflect the growing emphasis on environmental responsibility within the biopharmaceutical industry.
How Carbon Intensive is I-Mab Biopharma's Industry?
How Carbon Intensive is I-Mab Biopharma's Location?
I-Mab Biopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
I-Mab Biopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
